| The use of recombinant activated FVII in postpartum hemorrhage. | |
| | |
MedLine Citation:
|
PMID: 20142658 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Severe bleeding remains a leading cause of morbidity and mortality in obstetrics. The first-line standard treatment of massive postpartum hemorrhage (PPH) includes medical measures directed at improving uterine tone, replacement of lost intravascular volume, blood and coagulation factors, and surgical or invasive procedures. Recently, a number of case reports or case series have reported the successful "off-label" use of recombinant activated factor VII (rFVIIa) in PPH unresponsive to conventional treatments. In this review, a critical analysis of the published literature on the use of rFVIIa in severe PPH was performed. Overall, a total of 272 PPH women were collected among the largest case series and/or international registries. No randomized controlled trials have been conducted in this area. Currently, the literature data suggest that, at a median dose of 81.5 microg/kg, rFVIIa is effective in stopping or reducing bleeding in 85% of the cases. Finally, on the basis of the evidence from the literature and on own experience, we included some recommendations and an algorithm on the therapeutic role of rFVIIa in the management of PPH. |
| | |
Authors:
|
Massimo Franchini; Massimo Franchi; Valentino Bergamini; Martina Montagnana; Gian Luca Salvagno; Giovanni Targher; Giuseppe Lippi |
Related Documents
:
|
14886758 - Evaluation of a new method of dust control. 12884468 - Annular erythema responding to tacrolimus ointment. 12841828 - Melatonin for the treatment of tardive dyskinesia. 3158508 - Ciclopirox olamine 1% cream. a preliminary review of its antimicrobial activity and the... 15273858 - Cavernous angioma of the cauda equina: case report. 6683258 - Erythrocyte glucose-6-phosphate dehydrogenase isoenzyme phenotypes in leprosy. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Clinical obstetrics and gynecology Volume: 53 ISSN: 1532-5520 ISO Abbreviation: Clin Obstet Gynecol Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-09 Completed Date: 2010-05-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0070014 Medline TA: Clin Obstet Gynecol Country: United States |
Other Details:
|
Languages: eng Pagination: 219-27 Citation Subset: IM |
Affiliation:
|
Department of Pathology and Laboratory Medicine, University Hospital of Parma, Immunohematology and Transfusion Center, Parma, Italy. mfranchini@ao.pr.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Algorithms Factor VIIa / administration & dosage, therapeutic use* Female Hemostatics / administration & dosage, therapeutic use* Humans Off-Label Use Postpartum Hemorrhage / drug therapy* Pregnancy Recombinant Proteins / administration & dosage, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Hemostatics; 0/Recombinant Proteins; 0/recombinant FVIIa; EC 3.4.21.21/Factor VIIa |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Endovascular treatment of postpartum hemorrhage.
Next Document: Placenta accreta and postpartum hemorrhage.